NET INCOME ROSE MORE THAN 2 FOLD THIS QUARTER..
Not a surprise, BSX has had massive layoffs over the past year. The only way BSX can make their "net income" number look good is through massive headcount reduction and other cost-cutting measures. What really counts is making product and selling more of it, which is something BSX has failed to do consistently over the past 3 years. The past quarter was no surprise as revenues in their bread and butter divisions continued to plummet relative to the competition, indicating that BSX is still losing market share.
BSX cannot continue growing earnings though layoffs, eventually they will run out of people to fire.
"US CRM sales were down 14% this quarter, worse than St. Jude's (-7%) performance (and Medtronic (MDT ) won't report for a while). ICD revenue fell 12% (St. Jude's fell 2%), indicating that BSX continues to lose share despite some controversy with St. Jude's leads."
http://seekingalpha.com/article/510521-boston-scientific-has-the-tools-but-does-it-have-the-talent?source=yahoo
"Global sales of coronary stent system (within Interventional Cardiology) at $387 million declined 5.8% due to disappointing performance from both drug-eluting stents (“DES”) that declined 4.2% to $363 million and bare-metal stents that plunged 20% to $24 million."
http://finance.yahoo.com/news/boston-scientific-beats-penny-184527681.html
by the way, you claimed that BSX would be in the $7-8 range by April, yet the POS is still in the $5 range
http://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_B/threadview?bn=2713&tid=81539&mid=81561
What do you have to say for yourself? You were wrong again.